- Home
- PHI vs PCVX Comparison
PHI vs PCVX Comparison
Compare PHI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHI
- PCVX
- Stock Information
- Founded
- PHI 1928
- PCVX 2013
- Country
- PHI Philippines
- PCVX United States
- Employees
- PHI N/A
- PCVX N/A
- Industry
- PHI Telecommunications Equipment
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- PHI Telecommunications
- PCVX Health Care
- Exchange
- PHI Nasdaq
- PCVX Nasdaq
- Market Cap
- PHI 4.1B
- PCVX 4.0B
- IPO Year
- PHI 1953
- PCVX 2020
- Fundamental
- Price
- PHI $19.07
- PCVX $41.62
- Analyst Decision
- PHI Hold
- PCVX Strong Buy
- Analyst Count
- PHI 1
- PCVX 8
- Target Price
- PHI N/A
- PCVX $114.17
- AVG Volume (30 Days)
- PHI 138.2K
- PCVX 2.0M
- Earning Date
- PHI 11-11-2025
- PCVX 11-04-2025
- Dividend Yield
- PHI 6.35%
- PCVX N/A
- EPS Growth
- PHI 20.57
- PCVX N/A
- EPS
- PHI 2.62
- PCVX N/A
- Revenue
- PHI $3,879,170,293.00
- PCVX N/A
- Revenue This Year
- PHI $3.27
- PCVX N/A
- Revenue Next Year
- PHI $3.07
- PCVX N/A
- P/E Ratio
- PHI $7.28
- PCVX N/A
- Revenue Growth
- PHI 2.02
- PCVX N/A
- 52 Week Low
- PHI $18.61
- PCVX $27.66
- 52 Week High
- PHI $27.73
- PCVX $118.62
- Technical
- Relative Strength Index (RSI)
- PHI 37.27
- PCVX 72.10
- Support Level
- PHI $18.69
- PCVX $31.89
- Resistance Level
- PHI $19.08
- PCVX $43.76
- Average True Range (ATR)
- PHI 0.34
- PCVX 1.88
- MACD
- PHI 0.08
- PCVX 1.04
- Stochastic Oscillator
- PHI 29.28
- PCVX 82.12
About PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.